AHA comments on national security investigation of pharmaceutical imports

May 06, 2025 - 02:46 PM
MEDpac-comment-letter

AHA today comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients imports. The AHA urged the administration to maintain tariff exceptions, particularly for products already experiencing shortages and for countries that produce a significant portion of the U.S. market supply of pharmaceuticals and pharmaceutical ingredients.

鈥淭he lives of patients often depend on the ready availability of drugs to respond to emergent conditions like heart attacks and infections, and other critical illnesses like cancer and organ failure. The supply chain for pharmaceutical products is highly complex and requires hospitals to draw on both domestic and international sources,鈥 the AHA said. 鈥淔or many patients, even a temporary disruption in their access to these needed medications could put them at significant risk.鈥

Related News Articles

Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs鈥
Headline
The Food and Drug Administration March 14 released a notice on a nationwide shortage of hemodialysis tubes expected to last through early fall. On Jan. 8, B.鈥
Headline
The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize the availability of vital鈥
Headline
Baxter Jan. 28 announced that IV solutions production has been restarted on all manufacturing lines at its North Carolina site impacted by Hurricane Helene in鈥
Headline
Baxter notified customers on Jan. 22 that allocations for two sodium chloride IV solutions have been increased to 100%. According to Baxter, the products will鈥
Headline
After incurring damage from Hurricane Helene on Sept. 27, Baxter reports that as of Dec. 19, nearly all of its manufacturing lines in its North Cove, N.C鈥